News

Latest news

Hide mandatory notifications of trade

Bionor Pharma Appoints Synne H Røine as Chief Financial Officer

Oslo 01.03.2013 - The Appointment Strengthens Bionor Pharma’s Management Team and Presence in the Financial Market

(Oslo, Norway 1 March 2013)  Bionor Pharma ASA (OSE: BIONOR) today announced that Synne H Røine has been appointed Chief Financial Officer of Bionor Pharma ASA, and will start 1 June 2013 at the latest.
Synne H Røine (33) has held the position as Chief Financial Officer of Pronova BioPharma ASA since July 2009. She is a Norwegian citizen.

 “Synne Røine is a highly competent CFO with relevant experience from a fast growing public biotech company,”says CEO Dr. Anker Lundemose. “I strongly feel she will be able to add significant value to Bionor Pharma.
I am pleased to welcome her onboard the team and look forward to working with her in the exciting times ahead of us”.

Ms Røine holds a Master’s degree in business administration from Université des Sciences Sociales, Toulouse, France. She has worked in Pronova since 2005 where she has played a key role in Pronova’s financial team from the IPO in 2007 to the acquisition of the company by BASF in January 2013. Ms. Røine has held various positions in Pronova through which she has gained broad operational, financial and
strategic experience.

Bionor Pharma ASA

Dr. Anker Lundemose, CEO

Hilde Aalling Syvertsen,
-Director Communications & Corporate Affairs 

Tel +47 23 01 09 60

About Bionor Pharma ASA
Bionor Pharma is a leading vaccine company, listed on the Oslo Stock Exchange. The Company's investments in developing therapeutic vaccines exceed US$ 80 million, and the Company has secured funding of planned scientific and business related activities until mid 2014.
Bionor Pharma's vaccines are based on the proprietary technology platform developed following more than two decades of research on peptides, and they are designed to safely stimulate the immune system to combat viral diseases.
 
HIV vaccines - foremost in the development
The Company’s lead HIV candidate, Vacc-4x, has been investigated as a therapeutic vaccine in a large exploratory phase II randomized, multinational (USA and 4 European countries), double-blind, placebo-controlled study. This study showed a statistically significant reduction in viral load. Bionor Pharma`s second HIV vaccine candidate, Vacc-C5, is designed to induce antibodies that potentially can reduce the harmful hyperactivation of the immune system caused by HIV infection, which leads to AIDS.

Bionor Pharma is currently conducting three clinical studies:
1. Vacc-4x in combination with Celgene`s immune modulator Revlimid® (Lenalidomide), in patients who fail to regain a normal immune system despite having a well-controlled viral load on conventional HIV medication (antiretroviral therapy, ART). The researchers at four clinics in Germany will in this placebo-controlled study investigate whether Revlimid enhances the effect of Vacc-4x.
2. Reboosting with Vacc-4x in patients from the phase II study (USA and 4 European countries), to investigate whether this can result in a further reduction in viral load. Approximately 30-40 patients from the large phase II study with Vacc-4x will take part at 10 clinics.
3. Clinical phase I/II study with Vacc-C5, at Oslo University Hospital will investigate safety and efficacy, and whether this vaccine leads to increased formation of antibodies against HIV in humans.

Bionor Pharma is exploring the possibility to combine Vacc-4x and Vacc-C5 into one vaccine (Vacc-HIV), which as a therapeutic and possibly preventive HIV vaccine potentially can eradicate HIV-infection.

Vaccines for other viral diseases
The Company's innovative technology platform is also well suited to develop vaccines for other viral diseases, including Influenza, HCV (Hepatitis C), CMV (Cytomegalovirus) and HPV (Human papillomavirus). The universal influenza vaccine (Vacc-Flu) is in preclinical phase of development.

More information about Bionor Pharma is available at www.bionorpharma.com


This information is subject of the disclosure requirements acc. to §5-12 vphl
(Norwegian Securities Trading Act).  Vacc-4x, Vacc-C5, Vacc-Flu, Vacc-HCV, Vacc-CMV  and Vacc-HPV are investigational treatments that have not been approved for marketing by any regulatory authority.